Human organs-on-chips for disease modelling, drug development and personalized medicine

Ingber, Donald E.

doi:10.1038/s41576-022-00466-9

Cited by 572 publications

(521 citation statements)

References 155 publications

Supporting

Mentioning

404

Contrasting

Order By: Relevance

“…MPS have also found several applications in different organs modelling, such as gut (Raimondi et al, 2019), liver (Banaeiyan et al, 2017), retina (Achberger et al, 2019), skin (Sutterby et al, 2020) and others reviewed by D.E. Ingber (Ingber, 2022). The microbiota-neurodegeneration hypothesis can be study by the interface between individual organ-on-chip as brain and gut tissues creating a barrier model and study the penetration of neurotoxins through microbiota (Raimondi et al, 2019;Ambrosini et al, 2020;Ceppa et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices

Miny

Maisonneuve²,

Quadrio

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The human brain is a complex organ composed of many different types of cells interconnected to create an organized system able to efficiently process information. Dysregulation of this delicately balanced system can lead to the development of neurological disorders, such as neurodegenerative diseases (NDD). To investigate the functionality of human brain physiology and pathophysiology, the scientific community has been generated various research models, from genetically modified animals to two- and three-dimensional cell culture for several decades. These models have, however, certain limitations that impede the precise study of pathophysiological features of neurodegeneration, thus hindering therapeutical research and drug development. Compartmentalized microfluidic devices provide in vitro minimalistic environments to accurately reproduce neural circuits allowing the characterization of the human central nervous system. Brain-on-chip (BoC) is allowing our capability to improve neurodegeneration models on the molecular and cellular mechanism aspects behind the progression of these troubles. This review aims to summarize and discuss the latest advancements of microfluidic models for the investigations of common neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices

Miny

Maisonneuve²,

Quadrio

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Despite all these challenges, OOAC has a promising future and is an actively pursued field. Readers are encouraged to read another recent review on the subject [ 142 ]. Microbiorobotics (MBR) can be deployed in an OOAC for multiple purposes, such as drug delivery, real-time monitoring of the physiology of tissues in the cellular environment, and as a testbed [ 143 ].…”

Section: Challenges and Future Perspectivementioning

confidence: 99%

Breakthroughs and Applications of Organ-on-a-Chip Technology

Koyilot¹,

Natarajan²,

Hunt

et al. 2022

Cells

View full text Add to dashboard Cite

Organ-on-a-chip (OOAC) is an emerging technology based on microfluid platforms and in vitro cell culture that has a promising future in the healthcare industry. The numerous advantages of OOAC over conventional systems make it highly popular. The chip is an innovative combination of novel technologies, including lab-on-a-chip, microfluidics, biomaterials, and tissue engineering. This paper begins by analyzing the need for the development of OOAC followed by a brief introduction to the technology. Later sections discuss and review the various types of OOACs and the fabrication materials used. The implementation of artificial intelligence in the system makes it more advanced, thereby helping to provide a more accurate diagnosis as well as convenient data management. We introduce selected OOAC projects, including applications to organ/disease modelling, pharmacology, personalized medicine, and dentistry. Finally, we point out certain challenges that need to be surmounted in order to further develop and upgrade the current systems.

show abstract

“…8,9 Microfluidics has since then raised interest in a constantly increasing range of applications, taking advantage of several unique features: i/in direct inspiration from microelectronics, microfluidics allows to achieve high integration, automation, and parallelization of multiple steps (leading to the concept of "microfluidic processor" and "Micro-Total Analysis System", a term first coined by Widmer and Manz 10 ); ii/microfluidics allows the reliable manipulation of sub-microliter quantities of fluids, and thus a dramatic reduction in this device's sizes and the required sample and reagent quantities; iii/finally, microfluidics has also opened the route to intrinsically new concepts, such as "digital PCR" 11,12 or "organs on chip". [13][14][15] These intrinsic advantages have resonated with biological and medical markets, in which reagents and samples can be extremely limited and expensive, and the development of systems in biology and molecular medicine has called for massively parallel analyses. In 2013, the microfluidic market was valued at US$ 1.6 billion, 16 and is expected to reach US$ 44.0 billion by 2025.…”

Section: Introductionmentioning

confidence: 99%